TY - JOUR
T1 - Evidence-based clinical standard for the diagnosis and treatment of invasive lung aspergillosis in the patient with oncohematologic disease
AU - Cortés, Jorge Alberto
AU - Rodríguez-Lugo, Diego Andrés
AU - Valderrama-Rios, Martha Carolina
AU - Rabagliati, Ricardo
AU - Capone, Domenico
AU - Álvarez-Moreno, Carlos Arturo
AU - Varón-Vega, Fabio
AU - Nocua-Báez, Laura Cristina
AU - Diaz-Brochero, Cándida
AU - Enciso Olivera, Leonardo
AU - Cuervo-Maldonado, Sonia Isabel
AU - Thompson, Luis
AU - Corzo-León, Dora E.
AU - Cuéllar, Luis E.
AU - Vergara, Erika Paola
AU - Riera, Fernando
AU - Cornejo-Juárez, Patricia
AU - Rojas, Rita
AU - Gómez, Beatriz L.
AU - Celis-Ramírez, Adriana Marcela
AU - Sandoval-Gutiérrez, José Luis
AU - Sarmiento, Mauricio
AU - Ochoa, Diana Lorena
AU - Nucci, Marcio
N1 - Publisher Copyright:
© 2025 Sociedade Brasileira de Infectologia
PY - 2025/3/1
Y1 - 2025/3/1
N2 - Aspergillosis is a disease caused by the filamentous fungus Aspergillus spp. with a spectrum of clinical presentation that includes invasive and noninvasive forms. The invasive clinical presentation of aspergillosis most frequently affects people with compromised immune systems. In patients with oncohematologic pathology, invasive lung aspergillosis is a significant opportunistic mycosis, because it occurs frequently and has a major impact on morbidity, mortality, and high costs. The global problem of antimicrobial resistance, to which improper use of antifungals contributes, has put Aspergilus spp. in the spotlight, so it is important to generate guidelines for guidance in the proper use of antifungals in the management of invasive lung aspergillosis, to obtain better clinical outcomes and promote rational use of antifungals. This guideline contains recommendations for diagnosing and treating invasive lung aspergillosis in patients with oncohematologic disease, based on evidence and defined through a participatory process of expert consensus, for the Latin American context.
AB - Aspergillosis is a disease caused by the filamentous fungus Aspergillus spp. with a spectrum of clinical presentation that includes invasive and noninvasive forms. The invasive clinical presentation of aspergillosis most frequently affects people with compromised immune systems. In patients with oncohematologic pathology, invasive lung aspergillosis is a significant opportunistic mycosis, because it occurs frequently and has a major impact on morbidity, mortality, and high costs. The global problem of antimicrobial resistance, to which improper use of antifungals contributes, has put Aspergilus spp. in the spotlight, so it is important to generate guidelines for guidance in the proper use of antifungals in the management of invasive lung aspergillosis, to obtain better clinical outcomes and promote rational use of antifungals. This guideline contains recommendations for diagnosing and treating invasive lung aspergillosis in patients with oncohematologic disease, based on evidence and defined through a participatory process of expert consensus, for the Latin American context.
KW - Antifungal agents
KW - Hematologic neoplasms
KW - Invasive pulmonary aspergillosis
KW - Latin America
UR - https://doi.org/10.1016/j.bjid.2025.104517
UR - https://www.mendeley.com/catalogue/0d2f45b5-88c6-391f-9af4-c1d92997c777/
UR - http://www.scopus.com/inward/record.url?scp=85218442830&partnerID=8YFLogxK
U2 - 10.1016/j.bjid.2025.104517
DO - 10.1016/j.bjid.2025.104517
M3 - Article
SN - 1413-8670
VL - 29
JO - Brazilian Journal of Infectious Diseases
JF - Brazilian Journal of Infectious Diseases
IS - 2
M1 - 104517
ER -